ACTG A5178: LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 HIV患者经常合并感染丙型肝炎病毒（HCV），这两种感染的组合导致HCV感染进展为肝硬化的预后更差。 这是一项多中心、II期、开放标签、2组、长期（90周）试验，在HCV初治或标准IFNa未能清除HCV的患者中评价PEG-IFN（SQ qw）/利巴韦林（po qd），以确定其是否减缓肝纤维化进展速度。 在服用药物的同时，患者将接受静脉穿刺和肝活检。 在世界范围内，这是一个严重的问题，导致大量的发病率和死亡率。 这将试图确定这种形式的治疗是否以初步的方式起作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with HIV are often co-infected with Hepatitis C virus (HCV), and the combination of these two infections leads to a worse prognosis for the HCV infection with respect to progression to cirrhosis. This is a multicenter, phase II, open-label, 2-arm, long-term (90 wk) trial of PEG-IFN (SQ qw)/ribavirin (po qd) in patients who are HCV-therapy na¿ve or who have failed to clear HCV with standard IFNa to determine whether it slows the rate of progression of hepatic fibrosis. While taking the drugs patients will undergo venipunctures and liver biopsies. Worldwide this is a significant problem leading to a great deal of morbidity and mortality. This will seek to determine whether this form of therapy works in a preliminary fashion.